Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
The World Generic Market Report 2010
Management Report
Published: January 2010
Pages: 714
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 595.00 Buy Now!
Research from: Espicom
Sector: Prescription Medicines
This new 2 volume, 680-page edition is packed with facts, figures, analysis and statistics, that provides the most thorough analysis available on generic markets, products and companies and the issues they face.
Consolidation continues as US companies expand
Corporate consolidation continues to change the operating landscape, most notably the move by US company Mylan in its acquisition of Merck Generics and recent purchase of Arrow. These developments mark a more international shift in the US market and reflects growing price pressure in the domestic market.
EU gets tough on anti-competitive practice
Anxieties about anti-competitive practices in many European markets has seen the EU authorities take action, with a number of company offices raided as allegations are investigated. As recently as October 2009 it has been reported that many companies, including Sandoz, Teva and Ranbaxy have been the subject of such action.
Opportunities over the next 3 years look very promising
The generic sector is set for a boost as patents on a number of high-profile blockbuster products expire. Lipitor, Zyprexa, Actos, Avandia, Cymbalta and Plavix are just some of the leading brands likely to be challenged in the next few years.
Key company, market and product information
To understand the generic market, Espicom, publisher of the respected twice-monthly business publication World Generic Markets, has published The World Generic Market Report 2010. Packed with facts, figures, analysis and statistics, the new 2-volume 680-page edition provides the most thorough analysis available on generic markets, products and companies, and the issues they face.
Corporate consolidation continues to change the operating landscape, most notably the move by US company Mylan in its acquisition of Merck Generics and recent purchase of Arrow. These developments mark a more international shift in the US market and reflects growing price pressure in the domestic market.
EU gets tough on anti-competitive practice
Anxieties about anti-competitive practices in many European markets has seen the EU authorities take action, with a number of company offices raided as allegations are investigated. As recently as October 2009 it has been reported that many companies, including Sandoz, Teva and Ranbaxy have been the subject of such action.
Opportunities over the next 3 years look very promising
The generic sector is set for a boost as patents on a number of high-profile blockbuster products expire. Lipitor, Zyprexa, Actos, Avandia, Cymbalta and Plavix are just some of the leading brands likely to be challenged in the next few years.
Key company, market and product information
To understand the generic market, Espicom, publisher of the respected twice-monthly business publication World Generic Markets, has published The World Generic Market Report 2010. Packed with facts, figures, analysis and statistics, the new 2-volume 680-page edition provides the most thorough analysis available on generic markets, products and companies, and the issues they face.